checkAd
    Startseite > Aktien > Innate Pharma > Nachrichten
    Innate Pharma Aktie
    2,3550
     
    EUR
    +0,86 %
    +0,0200 EUR
    Letzter Kurs 15.05.24 Tradegate
    2,3200
     
    EUR
    432 STK
    Geldkurs 18:01:17
    2,3600
     
    EUR
    424 STK
    Briefkurs 18:01:17
    ISIN: FR0010331421 · WKN: A0LCUJ · SYM: IDD · Frankreich

    Neueste Nachrichten

    Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
    15.05.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
    14.05.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
    07.05.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
    15.04.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
    15.04.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
    10.04.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Announces Its Participation in Upcoming Investor Conference
    09.04.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
    05.04.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Reports Full Year 2023 Financial Results and Business Update
    21.03.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Announces Its Participation to Upcoming Investor Conference
    19.03.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
    14.03.24 · Business Wire (engl.) · Innate Pharma
    Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
    06.03.24 · Business Wire (engl.) · Innate Pharma